Key Takeaways:
- Apothékary raised $16 million in new funding, with $10 million coming from venture capital and $6 million from debt financing.
- The fresh funding will accelerate retail expansion and product innovation.
- This round bring the total Apothékary has raised to a total of about $32 million between venture capital and debt financing.
BeautyMatter 2026 FUTURE50 brand Apothékary raised $16 million in fresh capital.
WHO: Founded in 2020 by Shizu Okusa, Apothékary was inspired by her Japanese heritage and her experience with burnout while working on Wall Street. Apothékary is a plant medicine company offering clean, unadulterated herbal alternatives to over-the-counter supplements and quick fixes, which are often riddled with synthetic ingredients and additives. The natural remedies draw from traditions like Traditional Chinese Medicine, Kampo, and Ayurveda. All products are made with 100% certified organic ingredients and whole plants that don’t contain GMOs, fillers, artificial chemicals, sweeteners, gums, or additives.
WHY: The capital is about accelerating what the brand has spent the last several years building. They will continue investing in three key areas: product innovation, retail expansion, and AI.
IN THEIR OWN WORDS: "I’ve always believed your cap table should be a competitive advantage—not simply a source of capital," Shizu Okusa, founder of Apothékary, shared. "We intentionally built a group of investors that spans beauty, consumer, manufacturing, retail, healthcare and entrepreneurship. Whether it’s Shiseido’s global beauty expertise or founders and operators like Andy Dunn and Anne Mahlum, these are people I can call when we’re making...
